Sequential Therapies are the Future of Cancer Treatments

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Commsman
Posts: 8
Joined: Sat Mar 23, 2019 11:35 am

Sequential Therapies are the Future of Cancer Treatments

Post by Commsman » Sun Nov 17, 2019 9:42 pm

“Title: Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells (Abstract #2963)
Session Name: 635. Myeloproliferative Syndromes: Basic Science: Poster II
Session Date: Sunday, December 8, 2019
Session Time: 6:00 p.m. ET - 8:00 p.m. ET

The abstract reports results from early, nonclinical experiments on the potential effect of combining imetelstat and ruxolitinib on malignant myelofibrosis (MF) cells. The experiments explored the hypothesis that the combination of imetelstat and ruxolitinib might create a treatment regimen for MF that could be more efficacious than using either drug alone in reducing myelofibrosis hematopoietic stem cells and hematopoietic progenitor cells. In the experiments, the regimen of sequential treatment of ruxolitinib followed by imetelstat resulted in greater reductions in the MF hematopoietic stem and progenitor cells, compared to when either drug was used alone or simultaneously. In addition, the sequential treatment regimen did not affect normal hematopoietic stem and progenitor cells. As stated in the abstract, these findings suggest that an additive inhibitory activity against malignant myelofibrosis hematopoietic stem and progenitor cells can be achieved using a sequential treatment regimen of ruxolitinib followed by imetelstat.”

This is absolutely HUGE! The ramifications are far sweeping and portend an enormous potential for combination/sequential treatments for hematologic cancers across the board. This opens the door for ESA-Imetelstat sequential treatments, Radiation-Imetelstat Sequential treatments for AML, even Luspatercept-Imetelstat sequential treatments for MDS.

There are several reveals in the abstract. The 1st reveal is that Geron has indeed assembled a first-rate Research team and that they are indeed doing real scientific research on the Ruxolitinib – Imetelstat combo treatment opportunity for MF. Pre-clinical studies in both test tubes and mice are showing phenomenal results with a sequential treatment where Ruxolitinib (Jakifi) is used first followed by treatment with Imetelstat! “Compared to either drug alone or to MM control, Rux followed by Ime sequential treatment resulted in significant reductions in the numbers of MF…” Simultaneous treatment of Rux-Imet beat either Rux or Imet alone, but Sequential treatment with Rux followed by Imet consistently left all the other options in the dust!

The next reveal is that clearly Imetelstat will NOT replace Jakafi, but will indeed augment it and secure it’s future. I can only hope that the enemies of Imetelstat and Geron realize this sooner rather than later.

Post Reply